Skip to main content
. 2019 Jan 29;51(4):1324–1335. doi: 10.4143/crt.2018.653

Table 2.

Univariate and multivariate competing risk analyses of local progression after SRS in spinal metastasis

Characteristic No. of regions No. of events (%) Univariate
Multivariate
SHR 95% CI p-valuea) SHR 95% CI p-valueb)
Age (yr)
 ≤ 55 50 1 (2) Reference Reference
 > 55 99 6 (6) 3.409 0.430-27.026 0.246 1.744 0.256-11.843 0.569
Sex
 Male 90 6 (7) Reference
 Female 59 1 (2) 0.257 0.0316-2.095 0.204 NA
ECOG performance status
 0-1 137 6 (4) Reference
 2-4 12 1 (8) 1.939 0.230-16.366 0.543 NA
Primary tumor
 Lung 32 1 (3) Reference Reference
 Breast 25 0 0.000 NA < 0.001 0.000 NA < 0.001
 HCC 33 2 (6) 1.900 0.180-19.976 0.594 3.526 0.388-32.061 0.263
 RCC 10 2 (20) 7.885 0.783-79.411 0.080 5.002 1.028-24.341 0.046
 Others 49 2 (4) 1.362 0.130-14.333 0.797 1.490 0.103-21.624 0.770
Solitary metastasis
 No 129 7 (5) Reference Reference
 Yes 20 0 0.000 NA < 0.001 0.000 NA < 0.001
SINS criteria
 Tumor location
  Junctional (occiput-C2, C7-T2, T11-L1, L5-S1) 58 4 (7) Reference
  Mobile spine (C3-C6, L2-L4) 44 1 (2) 0.338 0.038-3.004 0.331 NA
  Semi-rigid (T3-T10) 47 2 (4) 0.649 0.121-3.496 0.615
 Pain
  Pain-free lesion 38 2 (5) Reference
  Occasional pain but not mechanical 78 2 (3) 0.526 0.075-3.694 0.518 NA
  Mechanical 33 3 (9) 1.978 0.337-11.620 0.450
 Bone lesion quality
  Lytic 102 6 (6) Reference Reference
  Mixed (lytic/blastic) 30 1 (3) 0.596 0.072-4.962 0.632 0.236 0.004-15.243 0.497
  Blastic 17 0 0.000 NA < 0.001 0.000 NA < 0.001
 Radiographic spinal alignment
  Normal alignment 143 7 (5) Reference
  Kyphosis/Scoliosis 5 0 0.000 NA < 0.001 NA
  Subluxation/Translation 1 0 0.000 NA < 0.001
 Vertebral body fracture
  None of the below 85 3 (4) Reference
  No collapse with > 50% body involved 28 1 (4) 1.045 0.107-10.186 0.970 NA
  < 50% collapse 28 3 (11) 3.405 0.706-16.421 0.127
  > 50% collapse 8 0 0.000 NA < 0.001
 Posterolateral involvement of spinal elements
  None of the above 83 2 (2) Reference Reference
  Unilateral 44 3 (7) 3.178 0.546-18.488 0.198 1.222 0.091-16.420 0.880
  Bilateral 22 2 (9) 3.827 0.539-27.187 0.180 1.576 0.208-11.909 0.660
SINS classification
 Stability 83 3 (4) Reference
 Intermediate stability 62 3 (5) 1.436 0.293-7.043 0.622 NA
 Instability 4 1 (25) 7.426 0.702-78.505 0.096
SRS dose (Gy)
 ≤ 20 135 7 (5) Reference Reference
 > 20 14 0 0.000 NA NA 0.000 NA < 0.001
ISRC sites number of treatment field
 1-3 62 0 Reference Reference
 4-6 87 7 (8) NA NA NA NA NA < 0.001
Bilsky
 Grade 0 80 2 (3) Reference Reference
 Grade 1 39 3 (8) 2.917 0.494-17.214 0.237 1.160 0.078-17.203 0.914
 Grade 2 21 0 0.000 NA < 0.001 0.000 NA < 0.001
 Grade 3 9 2 (22) 9.493 1.412-63.825 0.021 4.521 0.353-57.852 0.246

SRS, stereotactic radiosurgery; SHR, subhazard ratio; CI, confidence interval; NA, not applicable; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; SINS, Spinal Instability Neoplastic Score; ISRC, International Spine Radiosurgery Consortium.

a)

Univariate competing-risks regressions based on Fine and Gray’s proportional subhazards model,

b)

Multivariate competing-risks regressions based on Fine and Gray’s proportional subhazards model.